149 related articles for article (PubMed ID: 10966157)
1. Therapeutic proteins: a comparison of chemical and biological properties of uricase conjugated to linear or branched poly(ethylene glycol) and poly(N-acryloylmorpholine).
Schiavon O; Caliceti P; Ferruti P; Veronese FM
Farmaco; 2000 Apr; 55(4):264-9. PubMed ID: 10966157
[TBL] [Abstract][Full Text] [Related]
2. Biopharmaceutical properties of uricase conjugated to neutral and amphiphilic polymers.
Caliceti P; Schiavon O; Veronese FM
Bioconjug Chem; 1999; 10(4):638-46. PubMed ID: 10411462
[TBL] [Abstract][Full Text] [Related]
3. Immunological properties of uricase conjugated to neutral soluble polymers.
Caliceti P; Schiavon O; Veronese FM
Bioconjug Chem; 2001; 12(4):515-22. PubMed ID: 11459455
[TBL] [Abstract][Full Text] [Related]
4. Effects of modification of amino groups with poly(ethylene glycol) on a recombinant uricase from Bacillus fastidiosus.
Zhang C; Yang X; Feng J; Yuan Y; Li X; Bu Y; Xie Y; Yuan H; Liao F
Biosci Biotechnol Biochem; 2010; 74(6):1298-301. PubMed ID: 20530883
[TBL] [Abstract][Full Text] [Related]
5. Modification with polysialic acid-PEG copolymer as a new method for improving the therapeutic efficacy of proteins.
Wu J; Lu S; Zheng Z; Zhu L; Zhan X
Prep Biochem Biotechnol; 2016 Nov; 46(8):788-797. PubMed ID: 26829568
[TBL] [Abstract][Full Text] [Related]
6. Biochemical and biopharmaceutical properties of macromolecular conjugates of uricase with dextran and polyethylene glycol.
Yasuda Y; Fujita T; Takakura Y; Hashida M; Sezaki H
Chem Pharm Bull (Tokyo); 1990 Jul; 38(7):2053-6. PubMed ID: 1702692
[TBL] [Abstract][Full Text] [Related]
7. Comparison of modification of a bacterial uricase with N-hydroxysuccinimide esters of succinate and carbonate of monomethoxyl poly(ethylene glycol).
Zhang C; Yang X; Gao A; Hu X; Pu J; Liu H; Feng J; Liao J; Li Y; Liao F
Biotechnol Appl Biochem; 2014; 61(6):683-90. PubMed ID: 24512141
[TBL] [Abstract][Full Text] [Related]
8. Tissue distribution of 111In-labeled uricase conjugated with charged dextrans and polyethylene glycol.
Fujita T; Yasuda Y; Takakura Y; Hashida M; Sezaki H
J Pharmacobiodyn; 1991 Nov; 14(11):623-9. PubMed ID: 1725532
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic, biodistribution, and biophysical profiles of TNF nanobodies conjugated to linear or branched poly(ethylene glycol).
Vugmeyster Y; Entrican CA; Joyce AP; Lawrence-Henderson RF; Leary BA; Mahoney CS; Patel HK; Raso SW; Olland SH; Hegen M; Xu X
Bioconjug Chem; 2012 Jul; 23(7):1452-62. PubMed ID: 22731748
[TBL] [Abstract][Full Text] [Related]
10. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.
Bomalaski JS; Holtsberg FW; Ensor CM; Clark MA
J Rheumatol; 2002 Sep; 29(9):1942-9. PubMed ID: 12233890
[TBL] [Abstract][Full Text] [Related]
11. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
Ganson NJ; Kelly SJ; Scarlett E; Sundy JS; Hershfield MS
Arthritis Res Ther; 2006; 8(1):R12. PubMed ID: 16356199
[TBL] [Abstract][Full Text] [Related]
12. Biochemical and biopharmaceutical properties of PEGylated uricase.
Freitas Dda S; Spencer PJ; Vassão RC; Abrahão-Neto J
Int J Pharm; 2010 Mar; 387(1-2):215-22. PubMed ID: 19969053
[TBL] [Abstract][Full Text] [Related]
13. Polyethylene Glycol-Like Brush Polymer Conjugate of a Protein Drug Does Not Induce an Antipolymer Immune Response and Has Enhanced Pharmacokinetics than Its Polyethylene Glycol Counterpart.
Ozer I; Kelly G; Gu R; Li X; Zakharov N; Sirohi P; Nair SK; Collier JH; Hershfield MS; Hucknall AM; Chilkoti A
Adv Sci (Weinh); 2022 Apr; 9(11):e2103672. PubMed ID: 35133079
[TBL] [Abstract][Full Text] [Related]
14. Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase.
Kelly SJ; Delnomdedieu M; Oliverio MI; Williams LD; Saifer MGP; Sherman MR; Coffman TM; Johnson GA; Hershfield MS
J Am Soc Nephrol; 2001 May; 12(5):1001-1009. PubMed ID: 11316859
[TBL] [Abstract][Full Text] [Related]
15. Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma.
Chua CC; Greenberg ML; Viau AT; Nucci M; Brenckman WD; Hershfield MS
Ann Intern Med; 1988 Jul; 109(2):114-7. PubMed ID: 3289428
[TBL] [Abstract][Full Text] [Related]
16. Production of a thermostable uricase by a novel Bacillus thermocatenulatus strain.
Lotfy WA
Bioresour Technol; 2008 Mar; 99(4):699-702. PubMed ID: 17395458
[TBL] [Abstract][Full Text] [Related]
17. PEGylation enhancement of pH stability of uricase via inhibitive tetramer dissociation.
Tian H; Guo Y; Gao X; Yao W
J Pharm Pharmacol; 2013 Jan; 65(1):53-63. PubMed ID: 23215688
[TBL] [Abstract][Full Text] [Related]
18. Preparation and characterization of active site protected poly(ethylene glycol)-avidin bioconjugates.
Salmaso S; Semenzato A; Bersania S; Chinol M; Paganelli G; Caliceti P
Biochim Biophys Acta; 2005 Oct; 1726(1):57-66. PubMed ID: 15964691
[TBL] [Abstract][Full Text] [Related]
19. Uricase of Bacillus fastidiosus. Properties and regulation of synthesis.
Bongaerts GP; Uitzetter J; Brouns R; Vogels GD
Biochim Biophys Acta; 1978 Dec; 527(2):348-58. PubMed ID: 728443
[TBL] [Abstract][Full Text] [Related]
20. Impact of large aggregated uricases and PEG diol on accelerated blood clearance of PEGylated canine uricase.
Zhang C; Fan K; Ma X; Wei D
PLoS One; 2012; 7(6):e39659. PubMed ID: 22745806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
